Best Options Strategy for ORIC
Looking for the best options strategy for ORIC Pharmaceuticals, Inc. (ORIC)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live ORIC option chain right now, and a simple map from your view on ORIC to the strategy that fits it. Model any of them in the calculator before you trade.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical-stage biotech company focused on developing cancer treatments that target resistance mechanisms tumors use to evade existing therapies. The company's lead candidates are enozertinib, an orally available inhibitor designed to cross into the brain and block EGFR and HER2 mutations found in certain lung cancers, currently in early-stage clinical testing; and rinzimetostat, a different class of drug that works through the polycomb repressive complex 2 pathway and is being studied for prostate cancer. Both compounds remain in Phase 1b trials, where safety and early efficacy signals are being evaluated in patient populations.
ORIC generates its revenue potential through partnerships with established pharmaceutical companies. The company has agreements with Bayer and Johnson & Johnson to test rinzimetostat in combination with their respective hormone therapies for prostate cancer. These collaborations also provide supply arrangements, allowing ORIC to focus its resources on drug development while larger partners handle manufacturing and distribution logistics. Founded in 2014 and based in South San Francisco, the company remains pre-commercial, with no…
Today's top-scoring strategy for ORIC
Our engine ranks defined-risk strategies on the live ORIC chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | PUT | $7 | $0.60 |
| Sell | 1× | PUT | $11 | $2.60 |
| Sell | 1× | CALL | $11 | $1.38 |
| Buy | 1× | CALL | $15 | $0.33 |
Simulazione
Simulazione prospettica di 6,000 traiettorie di prezzo lognormali fino alla scadenza — non è un backtest storico.
Analisi della strategia
Greche vs prezzo
Prezzo × volatilità (oggi)
| −30% | −15% | IV | +15% | +30% | |
|---|---|---|---|---|---|
| $13 | $73 | $61 | $49 | $37 | $26 |
| $13 | $87 | $70 | $54 | $40 | $28 |
| $12 | $99 | $77 | $59 | $43 | $29 |
| $12 | $107 | $82 | $61 | $44 | $30 |
| $11 | $110 | $83 | $61 | $43 | $29 |
| $11 | $108 | $81 | $59 | $41 | $27 |
| $10 | $100 | $75 | $54 | $37 | $23 |
| $10 | $86 | $65 | $46 | $31 | $18 |
| $9 | $67 | $50 | $35 | $22 | $11 |
| $8 | $42 | $32 | $22 | $12 | $3 |
| $8 | $15 | $12 | $6 | $0 | −$6 |
Live scan from 2026-07-22 · quotes delayed ~15 minutes
Backtest storico: come si sarebbe comportata una Iron Butterfly su ORIC
Abbiamo simulato in modo approssimativo una Iron Butterfly su ORIC che avresti aperto ripetutamente nell'ultimo anno (93 ingressi storici, ciascuno mantenuto fino alla scadenza), con i premi d'ingresso modellati tramite Black-Scholes. Ecco come sarebbe andata sulla reale storia dei prezzi di ORIC — un backtest didattico, non una previsione dei rendimenti futuri.
In via approssimativa: i premi d'ingresso sono modellati con Black-Scholes sulla base della volatilità realizzata trailing, mantenuti fino alla scadenza e regolati contro il reale prezzo di chiusura storico. Fill reali, volatilità implicita e slippage differiscono — consideralo come contesto indicativo, non come rendimento esatto.
Implied volatility
ORIC is currently trading with high implied volatility, which makes its options expensive — and attractive to sell. On the options we scanned that was around 122% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on ORIC currently price in about 122% implied volatility, versus roughly 59% the stock has actually realised over the past month. That makes options relatively expensive — an edge for strategies that sell premium, such as credit spreads and iron condors.
Off that volatility, the options market is pricing a move of about ±$3,66 (±35%) in ORIC by 2026-08-21 — a range of roughly $6,92 to $14,24. Strikes inside that band hold most of the premium and see most of the action.
Across strikes, downside puts on ORIC trade at a higher implied volatility than upside calls — the market is paying up for crash protection. That skew favours selling put spreads or buying calls over symmetric trades.
In evidenza dalla option chain di ORIC: open interest, volume e skew
La option chain live di ORIC mostra un rapporto put/call sull'open interest di 0.04 (bullish-leaning (more calls)), con una volatilità implicita at-the-money intorno al 118.5%. L'open interest si concentra sulla call a 12 — un classico "muro" di resistenza — e sulla put a 6, un "muro" di supporto: esattamente gli strike a cui gli scrittori di opzioni sono più esposti verso la scadenza.
Istantanea di open interest, volume e volatilità implicita per la scadenza scansionata più vicina — contesto, non un segnale di trading.
Insider trading su ORIC (SEC Form 4)
Operazioni degli insider sul mercato aperto relative a ORIC negli ultimi sei mesi circa, tratte dalle comunicazioni SEC Form 4. Gli acquisti sul mercato aperto sono il segnale più raro e più forte — le vendite di routine effettuate nell'ambito di piani prestabiliti sono frequenti, quindi leggi un dato di vendita netta tenendolo presente.
| Insider | Azione | Azioni | Valore | Data |
|---|---|---|---|---|
| Heyman Richard A. | Vendita | 300 | $4K | 2026-07-06 |
| Piscitelli Dominic | Vendita | 52.000 | $703K | 2026-02-24 |
Fonte: comunicazioni SEC Form 4 tramite Finnhub. Solo acquisti (P) e vendite (S) sul mercato aperto — assegnazioni, esercizi di opzioni, donazioni e ritenute fiscali sono esclusi. Contesto informativo, non consulenza sugli investimenti.
Key figures
- Market cap
- $1.1B
- Beta (vs market)
- 1.01
- 52-week range
- $7.23–$14.93 (44% up the range)
- Short interest
- 21.6% of float · 11.3 days to cover
With 21.6% of ORIC's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.
How to choose an options strategy for ORIC
Start with your outlook on ORIC, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while ORIC stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →⧉ Embed this free calculator on your site →
How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open ORIC in the free calculator →
Domande frequenti
What is the best options strategy for ORIC?
It depends on your outlook. Bullish traders often use a long call or bull call spread on ORIC; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are ORIC options liquid enough to trade?
ORIC Pharmaceuticals, Inc. (ORIC) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade ORIC options?
Buying a single ORIC call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade ORIC or any security. Do your own research.
Cosa fa ORIC Pharmaceuticals, Inc.?
ORIC Pharmaceuticals, Inc. (ORIC) opera nel settore Biotechnology. La sezione "Informazioni su ORIC Pharmaceuticals, Inc." qui sopra offre un quadro più completo di ciò che fa l'azienda e di come genera profitti.
ORIC Pharmaceuticals, Inc. paga dividendi?
Qui non mostriamo un rendimento da dividendo confermato per ORIC Pharmaceuticals, Inc., quindi consideralo incerto: prima di scrivere delle call controlla il dividendo attuale e la data di stacco cedola (ex-dividend) presso il tuo broker — una data di stacco imminente può innescare un'assegnazione anticipata sulle call scritte in-the-money.
Tickers related to ORIC
Comparing ORIC with similar names can help you choose the best options strategy:
Informazioni sull’azienda
- Sede
- 240 E. Grand Ave, 2nd Floor, South San Francisco, CA, 94080, United States
- Settore
- Biotechnology
- Dipendenti
- 104
- CEO
- Dr. Jacob M. Chacko M.B.A., M.D.
- Telefono
- 650 388 5600
- Sito web
- www.oricpharma.com
Best Options Strategy by Ticker →
Solo per uso didattico. Le quotazioni sono ritardate di circa 15 minuti e nulla di ciò che è riportato qui è consulenza finanziaria. Il trading di opzioni comporta un rischio sostanziale di perdita. Privacy · Terms.